Axitinib/Axitinib medical insurance reimbursement policy and conditions in 2025

Axitinib/Axitinib (Axitinib) is a new oral targeted drug mainly used to treat metastatic renal cell carcinoma (mRCC). With the launch of the drug in the Chinese market, axitinib has been included in the Category B medical insurance reimbursement catalog, which means that patients who meet certain conditions can enjoy preferential medical insurance reimbursement. However, despite being included in medical insurance, the price of axitinib is still relatively high, usually above RMB 2,000. The specific cost may fluctuate due to different packaging specifications and market conditions.

The common packaging specifications of axitinib are1mg 14 tablets and 5mg 28 tablets, of which the 1mg specification is more commonly used for dose adjustment. In terms of medical insurance reimbursement conditions, patients need to meet specific indications, namely metastatic renal cell carcinoma, and must prove that other conventional treatments are ineffective or that the patient is drug-resistant. Patients need to provide relevant medical records and medical order certificates when purchasing drugs in order to enjoy medical insurance reimbursement. It is worth noting that although axitinib has been included in medical insurance, the reimbursement ratio of the drug will vary depending on the medical insurance policies and conditions of different regions. Patients need to understand the local medical insurance policies in advance to ensure smooth reimbursement.

In addition, due to the wide coverage of axitinib’s medical insurance reimbursement policy, some patients who are not eligible can still choose to purchase the drug at their own expense. Patients may face a greater financial burden when purchasing the drug at their own expense. Therefore, before using the drug, patients should discuss the drug use plan in detail with their doctor and choose the most appropriate treatment plan.

Overall, although axitinib has been included in medical insurance and provides certain reimbursement to eligible patients, patients still have to face high drug costs.

Reference materials:https://en.wikipedia.org/wiki/Axitinib